Further, as demonstrated recently, the loss of the BIR factor PIF-1 can be exploited for selective killing of cells made to rely on this HR subpathway by the concurrent deletion of FANCM, revealing a new synthetic lethality relationship and an approach to target PIF-1 mutant cancer cells (Li et al., 2021). Here, PIF1 is linked to cancer.